■ The first patient has been treated in the TRIDENT clinical trial, designed to demonstrate the Omni Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of Istent Inject, in lowering IOP in adults with OAG.

Sight Sciences, Inc., said the comparative TRIDENT study is evaluating safety and efficacy, including IOP reduction, for pseudophakic eyes in 3 arms: (1) canaloplasty alone with Omni, (2) sequential canaloplasty followed by trabeculotomy using Omni, and (3) implantation of 2 Istent Inject devices.

The next-generation Omni dispenses a higher volume of viscoelastic fluid than the existing system, the maker says, claiming that “to the best of our knowledge, TRIDENT is the largest standalone MIGS clinical trial ever initiated.”

“The OMNI Surgical System is defining a new interventional treatment paradigm in glaucoma management,” said TRIDENT investigator Karsten Klabe, MD, in a news release.